IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance Transparency and Improve Financial Reporting.

IGC Pharma has aligned its fiscal year with the calendar year, aiming to enhance transparency. The company develops cannabinoid-based treatments for Alzheimer's and other conditions, but faces financial challenges with negative margins and a low Altman Z-Score. IGC Pharma's revenue has grown 28.6% over three years, but it has a negative operating margin of -731.83% and a net margin of -582.82%. The company's valuation metrics indicate a speculative growth profile, with a P/S ratio of 22.52 and a P/B ratio of 3.33. Analyst sentiment is cautious, with a target price of $3.63 and a recommendation score of 2, indicating a hold position.